September 10-13, 2013, Denver

In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.

The Stribild single-tablet regimen matched both Atripla and boosted atazanavir (Reyataz) in efficacy among people age 50 and older, who responded as well as younger patients, researchers reported at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver. Related studies showed that Stribild had durable efficacy through 3 years and caused fewer central nervous system (CNS) side effects than Atripla.

The 53nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) kicked off Tuesday and runs throughout the week in Denver. HIVandHepatitis.com will be on site to cover the latest research on HIV and hepatitis B and C.

The investigational HIV integrase inhibitor GSK1265744 was well tolerated with no notable safety concerns in a meta-analysis of 8 studies testing the drug as either a pill or a long-acting injection, researchers reported at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.

Antiretroviral treatment that requires only a single tablet taken once-daily were associated with better viral suppression, higher adherence, and lower likelihood of hospitalization, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver.